Title: Study of Serum IP-10 Level as a Predictor for Non Alcoholic Steatohepatitis (NASH) In Diabetic and Non Diabetic Patients
Authors: El Said Ibrahim, Doaa Hashad, Perihan Salem, Youssra Abo Elfotoh
DOI: http://dx.doi.org/10.18535/jmscr/v4i2.12
Non alcoholic liver disease (NAFLD) is a public health problem with high prevalence, high level of disability associated and high cost for the health system. Non alcoholic steato hepatitis (NASH) is among its spectrum where histopathological changes similar to those in alcoholic hepatitis were observed. Interferon gamma-induced protein 10 (IP-10) is secreted in response to proinflammatory cytokines where it plays an important role in directing migration of cells, thus, function to regulate cell trafficking. This work aimed to study the significance of serum IP-10 level as a marker for NASH in diabetic and non-diabetic patients. Also, to correlate its level in the studied groups with clinical and laboratory findings. Key words: NAFLD, NASH, cytokines, chemokines, IP-10, type II DM.
1. Okanoue T, Umemura A, Yasui K, Itoh Y. Nonalcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan. J Gastroen Hepatol 2011; 26: 153–62. 2. Brunt EM. Nonalcoholic fatty liver disease: what the pathologist can tell the clinician. Dig Dis 2012; 30(1): 61–8. 3. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009; 29: 113–9. 4. Otgonsuren M, Stepanova M, Gerber L, Younossi ZM. Anthropometric and clinical factors associated with mortality in subjects with nonalcoholic fatty liver disease. Dig Dis Sci 2013; 58: 1132–40. 5. Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther 2012; 36: 815–23. 6. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73. 7. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36: 1349-54. 8. Chitturi S, Farrell GC. Etiopathogenesis of non alcoholic steatohepatitis. Semin Liver Dis 2001; 21(1): 27-41. 9. Day CP. From fat to inflammation. Gastroenterology 2006; 130: 207-10. 10. Tosello TAC, Landes SG, Nguyen V, Novobrantseva T, Young S. Kuppfer Cells Trigger Nonalcoholic Steatohepatitis Development in Diet-induced Mouse Model through Tumor Necrosis Factor-α Production. J Biol Chem 2012; 287(48): 40161–72 11. Chen X, Xun K, Chen L, Wang Y. TNF-alpha, a potent lipid metabolism regulator. Cell Biochem Funct 2009; 27(7): 407-16. 12. Hassanshahi G, Jafarzadeh A, Ghorashi Z, Zia Sheikholeslami N, Dickson AJ. Expression of IP-10 chemokine is regulated by pro-inflammatory cytokines in cultured hepatocytes. Iran J Allergy Asthma Immunol 2007; 6(3): 115-21. 13. Callewaere C, Banisadr G, Rostene W, Parsadaniantz SM. Chemokines and chemokine receptors in the brain: implication in neuroendocrine regulation. J Mol Endocrinol 2007; 38: 355-63. 14. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemotractant protein-1 (MCP-1): An overview. Journal of Interferon & Cytokine Research 2008; 29(6): 313-26. 15. Neville LF, Mathiak G, Bagasra O. The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 1997; 8: 207-19. 16. Luster AD, Unkeless JC, Ravetch JV. Gamma-interferon transcriptionally regulates an early response gene containing homology to platelet proteins. Nature 1985; 315: 672-6. 17. Abe T, Fukuhara T, Wen X, Ninomiya A, Moriishi K, Maehara Y, et al. CD44 participates in IP-10 induction in cells in which hepatitis C virus RNA is replicating, through an interaction with Toll-like receptor 2 and hyaluronan. J Virol 2010; 86 :6159–70. 18. Zhou Y, Wang S, Ma JM, Lei Z, Zhu HF, Lei P, et al. Hepatitis B virus protein X-induced expression of the CXC chemokine IP-10 is mediated through activation of NF-kappa B and increases migration of leukocytes. J Biol Chem 2010; 285: 12159–68. 19. Harvey CE, Post JJ, Palladinetti P, Freeman AJ, Ffrench RA, Kumar RK, et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol 2003; 74: 360–9. 20. Yoneyama H, Kai Y, Koyama J, Suzuki K, Kawachi K, Narumi S, et al. Neutralization of CXCL10 accelerates liver regeneration in carbon tetrachloride-induced acute liver injury. Med Mol Morphol 2007; 40: 191–7. 21. Nagpal ML, Davis J, Lin T. Overexpression of CXCL10 in human prostate LNCaP cells activates its receptor (CXCR3) expression and inhibits cell proliferation. Molecular basis of disease 2006; 1762: 811-8. 22. Booth V, Keizer DW, Kamphuis MB, Clark-Lewis I, Sykes BD. The CXCR3 binding chemokine IP-10/CXCL10: structure and receptor interactions. Biochemistry 2002; 41(33): 10418–25. 23. Bertola A, Bonnafous S, Anty R, Patouraux S, Saint-Paul MC, Iannelli A, et al. Hepatic Expression Patterns of Inflammatory and Immune Response Genes Associated with Obesity and NASH in Morbidly Obese Patients. Plos 2010; 10: 1371. 24. Zhang X, Shen J, Man K, Chu ES, Yau TO, Sung JC, Go MY, Deng J, Lu L, Wong VW, Sung JJ, Farrell G, Yu J. CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatoh-epatitis. J Hepatol 2014; 61: 1365–75. 25. Herder C, Haastert B, Müller-Scholze S, Koenig W, Thorand B, Holle R, Wichmann HE, Scherbaum WA, Martin S, Kolb H. Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes 2005; 54(2): 11–7. 26. Chia-Chu C, Chia-Lin W, Wei-Wen S, Kai-Lun S, Der-Cherng T, Chen-Te C, Ting-Yu C, Chew-Teng K , Hung-Ming W. Interferon gamma-induced protein 10 is associated with insulin resistance and incident diabetes in patients with nonalcoholic fatty liver disease. Scientific Reports 2015; 5: 10096. 27. Morimoto J, Yoneyama H, Shimada A, ShigiharaT, Yamada S, Oikawa Y. CXC chemokine ligand 10 neutralization suppresses the occurrence of diabetes in nonobese diabetic mice through enhanced beta cell proliferation without affecting insulitis. J Immunol 2004; 173: 7017–24. 28. Shimada A, Morimoto J, Kodama K, Suzuki R, Oikawa Y, Funae O, Kasuga A. Elevated serum IP-10 levels observed in type 1 diabetes. Diabetes care 2001; 24: 510-5. 29. Pagano G, Pacini G, Musso G, GambinoP,Mecca F, Depetris N, Cassader M, David E, Cavallo-PerinP, Rizzetto M.D.Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Furthe evidence for an etiologic association .Hepatology 2002; 2:367-72. 30. Hintermann E, Bayer M, Pfeilschifter JM, Luster AD, Christen U. CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactive-ation. J Autoimmun 2010; 35: 424–35. 31. Arun J, Clements RH, Lazenby AJ, Leeth RR, Abrams GA. The prevalence of nonalcoholic steatohepatitis is greater in morbidly obese men compared to women. Obes Surg 2006; 16(10): 1351-8. 32. Sligte KT, Bourass I, Sels JP, Driessen A, Stockbrugger RW, Koek GH. Non-alcoholic steatohepatitis: review of a growing medical problem. Eur J Intern Med 2004; 15(1): 10-21. 33. Bazick J, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, Doo E, Lavine J, Loomba R. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care 2015; 38(7): 1347-55. 34. Luyckx FH, Scheen AJ. Non alcoholic steatohepatitis and insulin resistance: interface between gastroenterologists and endocrinologists. Acta Clinica Belgica 2003; 58: 106-16. 35. Marchesini G, Elisabetta B, Gabriele F, Fernanda C, Marco L,Rita M et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917–23 36. Hsien-Liang H, Wen-Yuan L, Long-Teng L, Hsih-Hsi W, Wei-Jei L. Metabolic syndrome is related to non-alcoholic steato- hepatitis in severely obese subjects. Obesity Surgery 2007; 17(11): 1457-63. 37. Gupte A, Deepak A, Subjash A, Rajiv B, Pramod K, Snehansu P, Nikhil P, Aruna M, Anjal A, Hafeez U. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. Journal of Gastroenterology and Hepatology 2004; 19(8): 854–8. 38. Kenneth C. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Current Opinion in Endocrinology, Diabetes & Obesity 2009; 16(2): 141–9. 39. Prashanth M, Ganesh HK, Vimal MV, John M, Bandga T, Shashank R J, Shah SR, Rathi PM, Josh AS, Hemangini T, Menon PM, Shah SH, Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus. JAPI 2009; 57: 209. 40. Younossi ZM. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004; 2: 262–5. 41. Park SK. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology 2013; 57: 1378–83. 42. Jason MH, Alex H, Geoffrey C, James G, Adamandia Kriketos, Jacob George. Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology 2009: 40(1): 46–54. 43. Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, Goodman Z, Younossi ZM. Predictors of non alcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 2005; 15: 310-5. 44. Kotronen A, Yki-Jarvinen, H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb. Vasc. Biol 2008; 28: 27–38. 45. Haris EH. Elevated Liver Function Tests in Type 2 Diabetes. Clinical Diabetes 2005; 23(3): 115-9. 46. Siddharth V, Donald J, John H, Smruti RM. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver International 2013; 33(9): 1398-405. 47. Kocabay GL, Telci A, Tutuncu Y, Tiryaki B, Ozel S, Cevikbas U, Okten A, Satman I. Alkaline phosphatase: can it be considered as an indicator of liver fibrosis in non-alcoholic steatohepatitis with type 2 diabetes. Bratisl Lek Listy 2011; 112(11): 626-9. 48. Sajadi SM, Khoramdelazad H, Hassanshahi G, Rafatpanah H, Hosseini J, Mahmoodi M, Arababadi MK, Derakhshan R, Hasheminasabzavareh R, Hosseini-Zijoud SM, Ahmadi Z. Plasma levels of CXCL1 (GRO-alpha) and CXCL10 (IP-10) are elevated in type 2 diabetic patients: evidence for the involvement of inflammation and angiogenesis/angiostasis in this disease state. Clin Lab 2013; 59(1-2): 133-7. 49. Jingfang L, Bingyin Sh, Shuixiang H, Xiaoli Y, Mark DP, Zhenjun Z. Changes to tear cytokines of type 2 diabetic patients with or without retinopathy.Molecular vision 2010; 16:2931-8. 50. Xu H, Nakayama K, Ogawa S, Sugiura A, Kato T, Sato T, Sato H, Ito S. Elevated plasma concentration of IP-10 in patients with type 2 diabetes mellitus. Nihon Jinzo Gakkai shi 2005; 47(5): 524-30.
Abstract
References
